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immune regulatory mechanisms, such as
immune checkpoints and co-stimulatory sig-
nals, has improved, it has become clear that earlier
approaches to immunotherapy for advanced cancer,
which sought primarily to enhance activation of
tumor-specific T cells and other immune effector
cells, were often inadequate to maintain an effective
anti-tumor immune response. The primary reason for
the disappointing results for immunotherapy trials in
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regulatory mechanisms that suppress the anti-tumor
immune response, mechanisms that function to
keep the immune response in check. The recent
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Open access under CC BY-NC-ND license.cancer. For the first time, immunotherapy has been
shown to improve overall survival (OS) in randomized
phase III trials in patients with advanced malignancies,
as opposed to just a few patients who achieve a
durable response. A review of the mechanism of action
of these and other approaches to cancer immunother-
apy is provided in the article by Mary L. Disis within
this supplement. The current article reviews available
data on immune checkpoint inhibitors and therapeutic
vaccines, with a focus on approved agents as well as
those in clinical development.DEVELOPMENT OF IPILIMUMAB FOR
MELANOMA
Ipilimumab is a monoclonal antibody (mAb) tar-
geting cytotoxic T-lymphocyte–associated antigen 4
(CTLA-4), the prototypical immune checkpoint first
described by Allison and colleagues in the mid-
1990s.1,2 Briefly, CTLA-4 is expressed on activated
T cells and counters the co-stimulatory signal pro-
vided by CD28, thereby downregulating T-cell acti-
vation. Thus, CTLA-4 blockade enhances T-cell
activation and proliferation. To date, the develop-
ment of ipilimumab has spanned nearly two decades
(Figure 1).3 Ipilimumab was approved in 2011 by the
US Food and Drug Administration (FDA) for the
treatment of advanced melanoma.4 This was consid-
ered a milestone event because ipilimumab is theology, Vol 41, No 5, Suppl 5, October 2014, pp S14-S29
Figure 1. Key development milestones of ipilimumab. Preclinical studies of CTLA-4 inhibition in murine tumor models
began in the mid-1990s in the academic laboratory of Dr James Allison. Ipilimumab was developed as a fully human
monoclonal antibody in 1999 and progressed through clinical development over the next decade. In 2011, ipilimumab
received regulatory approval in both the United States and the European Union for the treatment of patients with
unresectable or metastatic melanoma. Ongoing trials of ipilimumab are evaluating combination therapies, use in the
adjuvant setting, and efﬁcacy and safety in tumor types other than melanoma.3 Abbreviations: ASCO, American Society of
Clinical Oncology; CTLA-4, cytotoxic T-lymphocyte-associated antigen-4.
Current perspectives on immunotherapy S15first therapy shown to improve OS in a randomized
trial of patients with metastatic melanoma.5Success of Ipilimumab as Both First-Line and
Second-Line Therapy for Metastatic
Melanoma
Results from study MDX010-20, a multinational,
randomized, double-blind, phase III trial, supported
regulatory approval of ipilimumab for previously
treated patients with metastatic melanoma
(Table 1).6–19 In this study, patients were randomized
(3:1:1) to ipilimumab plus a glycoprotein 100 (gp100)
peptide vaccine (n¼ 403), ipilimumab alone (n¼ 137),
or gp100 alone (n ¼ 136). Ipilimumab (3 mg/kg) with
or without gp100 was administered once every 3 weeks
for up to four treatments. Treatment with ipilimumab
plus gp100 vaccine demonstrated a statistically signifi-
cant OS benefit compared to that of the OS benefit of
gp100 alone (median 10.0 months v 6.4 months; hazard
ratio [HR] ¼ 0.68; Po.001). Additionally, 1-year and 2-
year survival rates were nearly double for patients
treated with ipilimumab plus gp100 (43.6% and
21.6%, respectively) compared with 1-year and 2-year
survival rates for those treated with gp100 alone (25.3%
and 13.7%, respectively). Results also were consistently
in favor of ipilimumab plus gp100, regardless of disease
state at presentation, baseline serum lactate dehydrogen-
ase levels, or age.
Subsequently, study CA184-024, another multina-
tional, randomized, double-blind, phase III trial, com-
pared ipilimumab (10 mg/kg) plus dacarbazine
(850 mg/m2; n ¼ 250) with placebo plus dacarbazine(850 mg/m2; n ¼ 252), given at weeks 1, 4, 7, and 10
followed by dacarbazine alone every 3 weeks through
week 22, in treatment-naı¨ve patients with advanced
melanoma12 (Table 1). Median OS was significantly
longer for patients treated with ipilimumab plus
dacarbazine compared to the median OS of dacarba-
zine plus placebo (11.2 months v 9.1 months), and
survival rates were higher with ipilimumab plus
dacarbazine compared with those of dacarbazine plus
placebo at 1 year (47.3% v 36.3%), 2 years (28.5% v
17.9%), and 3 years (20.8% v 12.2%; HR ¼ 0.72;
Po.001). The addition of ipilimumab to dacarbazine
also resulted in a 24% reduction in the risk of
progression (HR ¼ 0.76; P ¼ .006). In these trials,
approximately 10% of patients experienced pro-
longed tumor regression. In fact, some patients from
the initial phase II trials of ipilimumab have remained
free of progression for more than 5 years.3,20
Recently, initial results of the randomized, double-
blind, placebo-controlled European Organization for
Research and Treatment of Cancer (EORTC) 18071
phase III trial of ipilimumab (10 mg/kg) as adjuvant
therapy for patients with resected melanoma were
reported13 (Table 1). Compared with placebo (n¼ 476),
ipilimumab (n ¼ 475) significantly improved
recurrence-free survival (RFS) at 3 years (46.5% v
34.8%; HR ¼ 0.75; P ¼ .0013), and this benefit was
consistent across subgroups.
Lessons Learned From Development of
Ipilimumab
The unprecedented activity of ipilimumab in
patients with metastatic melanoma is exciting but
Table 1. Key Published Monotherapy Clinical Trials of CTLA-4 Checkpoint Inhibitors in Solid Tumors6–19
Agent Phase Tumor Type Treatment Arms N
Primary
Endpoint Efﬁcacy Results Grade 3/4 AEs Status
Ipilimumab I Prostate
(hormone-
refractory)
Ipi 14 Z50%
PSA
decline
14% 1 asthenia, 1 limb pain,
1 dizziness (7.1%)
Completed6
I/II CRPC
(metastatic)
Ipi þ radiotherapy 33 Response 1 CR (11.3þ months),
6 SD
(2.8-6.1 months)
Colitis (16%),
hepatitis (10%)
Completed7
II ED-SCLC
(untreated)
Ipi þ pac/carb v
pbo (ctrl) þ
pac/carb
130 irPFS Phased ipi v ctrl:
HR 0.64; P ¼ .03
Rates of 17% and 21% for
phased and concurrent
(phased v concurrent:
12/7 fatigue, 0/5 rash,
2/0 pruritus,
10/0 arthralgia,
0/2 decreased appetite,
10/4 diarrhea)
Completed8
Concurrent ipi v ctrl:
HR 0.75; P ¼ .11
II NSCLC
(untreated)
Ipi þ pac/carb v
pbo (ctrl) þ
pac/carb
204 irPFS Phased ipi v ctrl:
HR 0.72; P ¼ .05
Rates of 15% and 20% for
phased and concurrent
(phased v concurrent:
5/8 fatigue, 3/3 rash,
2/0 arthralgia, 2/0
asthenia, 5/7 diarrhea,
2/1 nausea,
2/1 vomiting,
0/1 neuropathy,
3/0 sensory neuropathy)
Completed9
Concurrent ipi v ctrl:
HR 0.81; P ¼ .13
II Renal cell
carcinoma
Ipi (21 at lower
dose; 40 at
higher dose)
61 Response Low dose: 1 PR Low dose: 3 enteritis (14%) Completed10
High dose: 5 PR
(ORR ¼ 12.5%)
High dose: 13 enteritis,
1 hypophysitis, 1 adrenal
insufﬁciency, 1 aseptic
meningitis, 1 with
both enteritis
and hypophysitis
III Melanoma Ipi v ipi þ gp100
v gp100
676 OS 10.0 months
(ipi þ gp100) v
10.1 (ipi alone) v
6.4 months
(gp100 only)
Ipi þ gp100: derm (40%),
GI (32.1%), endo
(3.9%), other (3.2%),
hepatic (2.1%)
Completed11
Ipi alone: derm (43.5%),
GI (29%), endo (7.6%),
J.S.
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other (4.6%), hepatic
(3.8%)
III Melanoma Ipi þ dacarbazine
v dacarbazine
þ pbo
502 OS 47.3% v 36.2% at
1 year; 28.5% v
17.9% at 2 years;
20.8% v 12.2% at
3 years
Diarrhea (32.8%); increase
in ALT (29.1%); pruritus
(26.7%); increase in AST
(26.7%); rash (22.3%);
colitis (4.5%);
hepatitis (1.6%)
Completed12
III Melanoma Ipi v pbo 951 RFS 46.5% v 34.8% at
3 years
Ipi v pbo: GI (15.9% v
0.8%), hepatic (10.6% v
0.2%), endocrine
(8.5% v 0)
Ongoing13
ipi v pbo: HR 0.75;
P ¼ .0013
Tremelimumab I Hepatocellular
carcinoma
Tremelimumab 37 Response PR 17.6% AST (45%); hyponatremia
(30%); ALT (25%);
encephalopathy (15%);
acute renal failure,
syncope, total bilirubin
(10% each); skin rash,
diarrhea, diverticulitis,
depression,
GI hemorrhage,
cholangitis, pneumonia,
hypoalbuminemia,
thrombocytopenia,
neutropenia (5% each)
Completed14
I/II Melanoma Tremelimumab 28 þ 89 ORR 1 CR, 3 PR (phase II) 12 (27%) at 15 mg/kg Completed15
6 (13%) at 10 mg/kg
(phase II)
II Colorectal Tremelimumab 47 Response ORR 2.2% (1 PR) 5 diarrhea (11%),
1 ulcerative colitis,
1 fatigue, 1 autoimmune
thrombocytopenia, and
1 hypokalemia (2% each)
Completed16
II Melanoma Tremelimumab 246 ORR 6.6% ORR (16 PR) Diarrhea (11%), colitis
(4%), fatigue (2%)
Completed17
II Mesothelioma Tremelimumab 29 ORR 2 durable PR (7%);
median PFS of
6.2 months; median
OS of 10.7 months
GI (14%); hepatic (7%);
neurologic, pancreatic
(3% each)
Completed18
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J.S. WeberS18not without side effects. Because it “loosens the reins”
on T-cell activation and proliferation, ipilimumab can
potentially allow self-reactive T cells to proliferate, and
this has been associated with characteristic side effects
collectively referred to as immune-related adverse
events (irAEs). The most common irAEs are associated
with symptoms of diarrhea, nausea, constipation,
abdominal pain, vomiting, vitiligo, and rash.4,11,12
Approximately 60% of ipilimumab-treated patients in
study MDX010-20 experienced irAEs.11 In a small
proportion of patients, irAEs can be serious and may
include severe hepatitis, enterocolitis, hypophysitis,
pancreatitis, nephritis, and neuropathy.4 Due to the
risk of developing irAEs, close monitoring is essential
during anti-CTLA-4 therapy, and management guide-
lines recommend symptomatic treatment for mild
irAEs and dose delay/omission and intense monitoring
for moderate or persistent mild irAEs.4,21,22 In patients
with persistent or high-grade irAEs, ipilimumab should
be permanently discontinued and high-dose systemic
corticosteroid therapy should be initiated. The most
common irAEs typically resolve within 4–9 weeks of
onset, depending on the organ system involved.3
Ipilimumab also has unique patterns of clinical
response compared to that of chemotherapy, which
is generally associated with rapid but transient
responses in melanoma. The Response Evaluation
Criteria in Solid Tumors (RECIST), which defines
disease progression as the presence of new or
progressing lesions, was developed to provide uni-
form assessment of responses to chemotherapy.23
Ipilimumab therapy, on the other hand, may result in
unusual response patterns and kinetics, such as early
apparent disease progression followed by profound
and durable tumor regression, or initial regression of
established lesions despite development of new,
smaller lesions.24 Consequently, immune-related
response criteria and immune-related RECIST were
established to evaluate tumor response to ipilimu-
mab and other immunotherapies.25,26 These criteria
accommodate the presence of new lesions and do
not automatically assume progression when new
disease arises.Overview of Other Tumor Types Where
Ipilimumab Is Currently Being Investigated
Ipilimumab also has demonstrated activity in
other advanced cancers (Table 1), most notably
small cell lung cancer (SCLC), non-small cell lung
cancer (NSCLC), and prostate cancer. Ipilimumab
was evaluated in combination with standard
carboplatin-based doublet chemotherapy in two
phase II studies in treatment-naı¨ve patients with
SCLC or NSCLC.8,9 In both studies, a phased, but
not concurrent, schedule of ipilimumab (10 mg/kg)
plus paclitaxel (175 mg/m2) and carboplatin (area
Current perspectives on immunotherapy S19under the curve 6) significantly improved progres-
sion-free survival (PFS) compared to that of pacli-
taxel and carboplatin alone. In patients with SCLC,
median PFS was 6.4 months for patients treated with
ipilimumab plus paclitaxel and carboplatin versus
5.3 months for those treated with paclitaxel and
carboplatin alone (HR ¼ 0.64; P ¼ .03), in patients
with NSCLC, median PFS was 5.7 months versus
4.6 months, respectively (HR ¼ 0.72; P ¼ .05).
Phase III studies of ipilimumab are currently ongoing
in patients with newly diagnosed SCLC (NCT01450-
761) and NSCLC (NCT01285609). Ipilimumab (3, 5,
or 10 mg/kg) with or without a single dose of focal
radiotherapy was evaluated in a phase I/II study in
patients with metastatic castration-resistant prostate
cancer (mCRPC).7 Declines in prostate-specific anti-
gen (PSA)Z50% were observed in 22% of patients.
Ipilimumab is currently being evaluated in phase III
studies of patients with advanced prostate cancer
(NCT01057810 and NCT00861614). In addition,
numerous trials of ipilimumab are currently ongoing
in other solid tumors, including platinum-sensitive
ovarian cancer (NCT01611558), unresectable or
metastatic gastric cancer following chemotherapy
(NCT01585987), and in combination with chemo-
therapy in metastatic bladder cancer (NCT01524991).
Another CTLA-4 Inhibitor in Development:
Tremelimumab
Tremelimumab is another anti-CTLA-4 mAb in
development. Similar to data seen with ipilimumab,
tremelimumab demonstrated encouraging anti-
tumor activity with durable responses in phase I
and phase II studies in patients with metastatic
melanoma15,17 (Table 1). Based on these findings,
a phase III study comparing tremelimumab (15 mg/
kg once every 90 days) with physician’s choice of
chemotherapy (temozolomide or dacarbazine) was
conducted in patients with newly diagnosed meta-
static melanoma19 (Table 1). Tremelimumab failed
to improve OS compared to that achieved with
chemotherapy (12.6 months v 10.7 months;
HR ¼ 0.88; P ¼ .127), and clinical development in
melanoma was discontinued. More recently, trem-
elimumab has demonstrated activity in malignant
mesothelioma, metastatic colorectal cancer, and
hepatocellular carcinoma.14,16,18NEXT-GENERATION IMMUNE CHECKPOINT
INHIBITORS
The unprecedented activity of ipilimumab in
achieving durable objective responses and signifi-
cantly improving PFS and OS in advanced melanoma
has spurred the clinical development of other
immune checkpoint inhibitors. The agents farthestalong in clinical development are antibodies that
block programmed cell death 1 (PD-1) and pro-
grammed cell death ligand 1 (PD-L1). The primary
role of the PD-1/PD-L1 pathway is to limit T-cell
effector function in peripheral tissues. PD-1 engage-
ment on T cells results in T-cell exhaustion. Tumors
often express PD-L1, which binds to PD-1 on acti-
vated cytotoxic T cells and natural killer cells in the
tumor microenvironment, thereby inducing T-cell
dysfunction.27–35 At present, the most mature data
available for antibodies targeting this pathway are
from phase I/II clinical trials.Early Trials of Anti-PD-1/Anti-PD-L1 in
Melanoma
In 2013, anti-PD-1/anti-PD-L1 antibodies were
named “drug of the year”.36 This was due, in a large
part, to the exciting data reported from early phase
trials of nivolumab, pembrolizumab, and MPDL3280A
for treatment of patients with advanced melanoma
(Table 2).37–49 These studies demonstrated impres-
sive rates of response and prolonged duration of
response.
Nivolumab, a fully human immunoglobulin G4
(IgG4) anti-PD-1 mAb, was the first to be assessed in
patients with metastatic melanoma. Nivolumab was
evaluated in a phase I study in patients with a variety
of malignancies (n ¼ 296), including 107 with
advanced melanoma37–39,50 (Table 2). The objective
response rate (ORR) for the melanoma cohort was
31% (33 of 106), and OS rates were 61% at 1 year,
44% at 2 years, and 41% at 3 years. Grade 3 or grade
4 drug-related AEs occurred in 21% of patients, with
the most common being lymphopenia (3%), and
fatigue, increased lipase, diarrhea, and endocrine
disorders (2% each); no gradeZ3 drug-related pneu-
monitis was reported in the melanoma cohort. In a
phase I trial in patients with melanoma (N ¼ 105)
who were ipilimumab-naı¨ve or had progressed on
ipilimumab, treatment with nivolumab (1, 3, or
10 mg/kg) resulted in a median PFS of 4.2 months,
an estimated median OS of 16.7 months, and a 1-year
OS rate of 65%40 (Table 2). Of the 20 patients with
prior ipilimumab-induced grade 3/4 irAEs, only one
had a subsequent grade 3/4 irAE with nivolumab,
which was different from the toxicity seen with
ipilimumab. However, treatment-emergent grade 1/2
rash and injection reactions were more frequent. In
general, agents targeting PD-1/PD-L1 appear to have
a more favorable toxicity profile compared to the
toxicity profile of anti-CTLA-4, likely due to the
distinct biologic characteristics of the two pathways
(ie, PD-1/PD-L1 checkpoint interaction occurs pri-
marily at the tumor site and focuses on acti-
vated T cells, whereas the CTLA-4/B7 interaction
occurs mainly in lymphoid organs).36,51 Results from
Table 2. Key Published Monotherapy Clinical Trials of PD-1/PD-L1 Checkpoint Inhibitors in Solid Tumors37–49
Target/Agent Phase Tumor Type
Treatment
Arms N
Primary
Endpoint Efﬁcacy Results Grade 3/4 AEs Status
PD-1/ Nivolumab I Melanoma Nivolumab 107 ORR 31% ORR; median OS
16.8 mos; 1-year OS
61%; 2-year OS 44%;
3-year OS 41%
21% pts (3% lymphopenia;
2% fatigue, increase
lipase, diarrhea, hepatitis,
and endocrine disorders)
Ongoing37–39
Melanoma Nivolumab 105 ORR Median PFS 4.2 mos;
estimated median OS
16.7 mos; 1-year
OS 65%
Of 20 pts with prior ipi-
induced grade 3/4 irAEs,
1 had a subsequent
nivolumab-induced grade
3/4 irAE
Currently
recruiting40
NSCLC Nivolumab 127 ORR 16% ORR; median OS
9.2 and 9.6 mos
(squamous and
nonsquamous); 1 year
OS rate 44% and 41%
(squamous and
nonsquamous)
2% each of fatigue,
pneumonitis, and elevated
AST*
Ongoing38,41
Renal cell
carcinoma
Nivolumab 34 ORR 29% ORR; median
OS422 mos; 1 year
OS rate 70%
21% pts (including 6%
hypophosphatemia, 6%
respiratory disorders)
Ongoing38,42
PD-1/
Pembrolizumab
I Melanoma Pembrolizumab 135 ORR 38% ORR; median
PFS47 mos; 8 pts SD;
77% had tumor
shrinkage during study
13% pts, with 3 pts rash
(2%), 1 pt pruritus (1%),
2 pts fatigue (1%)
Completed43
Melanoma Pembrolizumab 221 ORR 2 mg/kg Q3W: 33% ORR;
median PFS 27 weeks;
24-week
PFS 51%
14% pts experienced grade
3/4 AEs
Currently
recruit-
ing44–46
10 mg/kg Q3W: 40%
ORR; median PFS 23
weeks; 24-week
PFS 48%
Ipi-naïve; combined dose
groups: 40% ORR;
median PFS 24 weeks;
24-week PFS 51%
J.S.
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Ipi-treated; combined
dose groups: 28% ORR;
median PFS 23 weeks;
24-week
PFS 44%
PD-1/ Pidilizumab I Hematologic
malig-
nancies
Pidilizumab 17 ORR 33% ORR (1 CR, 4 SD,
1 minimal response)
None Completed47
PD-L1/ BMS-
936559
I Melanoma BMS-936559 52 ORR 17% ORR (9 pts); 27% SD
(14 pts); 42% PFS at 24
weeks
3% (7 pts): 1 adrenaline
insufﬁciency,
1 pancreatitis, 1 vomiting,
1 chest pain, 1 sarcoidosis,
1 endophthalmitis,
1 elevated aspartate,
1 myasthenia gravis*
Completed48
NSCLC BMS-936559 49 ORR 10% ORR (5 pts); 12% SD
(6 pts); 31% PFS at 24
weeks
Ovarian BMS-936559 17 ORR 6% ORR (1 pt); 18% SD (3
pts); 22% PFS at 24
weeks
Renal cell
carcinoma
BMS-936559 17 ORR 12% ORR (2 pts); 41% SD
(7 pts); 53% PFS at 24
weeks
PD-L1/
MPDL3280A
I Solid tumors MPDL3280A 171 ORR 21% ORR (based on 122
pts); 24-week PFS: 44%
39% of pts (including
hepatitis, rash, colitis)
Ongoing49
n Grade 3/4 irAEs presented are for all tumor types included.
Abbreviations: AEs, adverse events; AST, aspartate aminotransferase; CR, complete response; ipi, ipilimumab; mos, months; NSCLC, non-small cell lung cancer; ORR, overall response
rate; OS, overall survival; PFS, progression-free survival; pt, patient; SD, stable disease; Q3W, every 3 weeks.
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J.S. WeberS22ongoing, randomized, phase III trials of nivolumab
versus physician’s choice (dacarbazine or carbopla-
tin with paclitaxel) in advanced melanoma
(NCT01721746), nivolumab versus dacarbazine in
untreated or advanced melanoma (NCT01721772),
and nivolumab or nivolumab plus ipilimumab versus
ipilimumab in untreated advanced melanoma
(NCT01844505) are eagerly awaited.
Pembrolizumab, a humanized IgG4 anti-PD-1
mAb, is being studied in both ipilimumab-naı¨ve
patients with melanoma and those previously treated
with ipilimumab. The ORR was 38% in a phase I
study of 135 patients with advanced melanoma, and
response rates did not differ between patients who
had (37%) or had not (38%) received prior ipilimu-
mab43 (Table 2). Responses were durable and over
81% of patients who had a response were still
receiving treatment at the time of the analysis.
Common treatment-related AEs included fatigue,
rash, pruritus, and diarrhea; most of the AEs were
low grade. The phase I KEYNOTE-001 study eval-
uated three doses of pembrolizumab (10 mg/kg
every 2 weeks, 10 mg/kg every 3 weeks, and
2 mg/kg every 3 weeks) in ipilimumab-naı¨ve
and ipilimumab-treated patients with melanoma
(N ¼ 221)44–46 (Table 2). Initial results showed that
the ORR was higher in patients treated with pem-
brolizumab 10 mg/kg every 3 weeks compared to
patients treated with pembrolizumab 2 mg/kg every
3 weeks (40% v 33%), and ORR was higher in
ipilimumab-naı¨ve patients compared to that of
ipilimumab-treated patients (40% v 28%). Approxi-
mately 14% of patients experienced drug-related
grade 3/4 AEs. Randomized phase II (NCT01704287)
and phase III (NCT01866319) studies evaluating pem-
brolizumab versus chemotherapy and ipilimumab,
respectively, are currently ongoing.
BMS-936559, a fully human IgG4 anti-PD-L1 mAb,
also was evaluated in patients with advanced mela-
noma. In a phase I study of 207 patients with
advanced malignancies, including 55 patients with
melanoma48 (Table 2), an objective response was
observed in nine of the 52 evaluable patients with
melanoma (17%), and five had a duration of response
of at least 1 year. Common treatment-related AEs
were fatigue, infusion reactions, diarrhea, arthralgia,
rash, nausea, pruritus, and headache; most of the AEs
were low grade. As of June 2014, however, no phase
II or phase III trials of BMS-936559 were listed
on clinicaltrials.gov.
MPDL3280A, a humanized anti-PD-L1 mAb, was
evaluated in a phase I dose-escalation study in patients
with solid tumors, including melanoma49 (Table 2). Of
the patients evaluable for efficacy (N ¼ 122), an ORR
of 21% was observed. Of those evaluable for safety
(N ¼ 171), none experienced dose limiting toxicities
and a maximum tolerated dose was not identified.Although no phase I or phase III trials of MPDL3280A
in melanoma were listed on clinicaltrials.gov as of June
2014, a phase III study in NSCLC is currently recruiting
(NCT02008227).
Comparison of Anti-PD-1/Anti-PD-L1 to
Anti-CTLA-4
Although there are currently no completed
randomized, head-to-head studies comparing anti-
PD-1/anti-PD-L1 and anti-CTLA-4 mAbs, the fact that
they both target immune checkpoint molecules
prompts a natural comparison. PD-1/PD-L1 and
CTLA-4 have distinct biologic properties, and pre-
clinical studies also suggest that the combination of
CTLA-4 and PD-1 blockade is more effective than
either alone. The CTLA-4 and PD-1 blockade
approach52 is currently being explored in a clinical
setting for treatment of advanced melanoma
(NCT01024231). Given a more tumor-specific mech-
anism of immune activation, existing data suggest
that PD-1/PD-L1 inhibitors may be more active and
less toxic than CTLA-4 inhibitors.53 The growing
body of data on expression of PD-1/PD-L1 as poten-
tial prognostic and predictive biomarkers also adds
to the rising interest in targeting this pathway for
cancer therapy.54
Ongoing Clinical Trials of Anti-PD-1/Anti-PD-
L1 in Multiple Tumor Types
In addition to the promising early phase results in
melanoma, nivolumab and BMS-936559 have dem-
onstrated impressive activity in NSCLC and renal cell
carcinoma, and pidilizumab has shown promising
results in hematologic malignancies38,41,42,47,48
(Table 2). Overall, these results suggest that target-
ing the PD-1/PD-L1 pathway has broad potential
across multiple tumor types.DEVELOPMENT OF SIPULEUCEL-T FOR
PROSTATE CANCER AND CURRENT USE
Sipuleucel-T is distinct from other marketed anti-
tumor treatments because it is an individually tailored
immunotherapeutic vaccine manufactured from
immune cells specific to each patient.55 In 2010,
sipuleucel-T was approved by the FDA based on a
demonstrated survival benefit in men with asympto-
matic/minimally symptomatic mCRPC.56 It is the first
approved autologous cellular immunotherapy to
improve OS in patients with advanced cancer.57
Developing sipuleucel-T for each patient involves
a multistep process57 (Figure 2). First, the patient’s
own peripheral blood mononuclear cells, including
autologous antigen-presenting cells (APCs) and T
cells, are harvested via leukapheresis. The harvested
cells are then cultured ex vivo with PA2024, a
Figure 2. Process of sipuleucel-t administration. Production of sipuleucel-T begins at an approved apheresis center. The
unprocessed cells from the leukapheresis procedure are then shipped to one of three manufacturer’s facilities for product
preparation. During a standard processing procedure, the cells are activated through co-culturing with PA2024. The
activated cells are then shipped back to the physician’s infusion center. This process is repeated three times for a standard
course of treatment.57
Current perspectives on immunotherapy S23recombinant fusion protein composed of prostatic
acid phosphatase (PAP), a prostate cancer-associated
antigen, and granulocyte-macrophage colony-stimu-
lating factor (GM-CSF). The GM-CSF component
stimulates maturation of APCs into mature DCs.
Following ex vivo activation, the mature APCs loaded
with PAP peptides in the context of the patient’s
type 1 and type 2 human leukocyte antigens are re-
infused into the patient where they can stimulate
CD4þ and CD8þ cells, thus potentially triggering an
immune response specifically against PAP-positive
PC cells.
A complete treatment course consists of three
doses administered at approximately 2-week inter-
vals57 (Figure 2). Each dose is manufactured approx-
imately 3 days prior to infusion. The first infusion
serves to prime the anti-tumor immune response,
and the two subsequent infusions boost that
response, which may result in long-lasting antigen-
specific cellular and humoral immune responses
to PAP.Clinical Trials Resulting in Approval of
Sipuleucel-T
To date, three randomized, double-blind, placebo-
controlled phase III trials of sipuleucel-T have been
completed in patients with mCRPC. The first two
trials, D9901 and D9902A, had identical designs.55,58
Patients with asymptomatic mCRPC were random-
ized 2:1 to receive sipuleucel-T or placebo, and were
followed for 36 months. In study D9901 (N ¼ 127)
there was a statistically nonsignificant improvement
in time to disease progression (TTP) for the
sipuleucel-T group compared to the TTP found with
the control group (HR 1.45; P ¼ .05). However, at 36months, there was a statistically significant 4.5-
month prolongation in OS with sipuleucel-T com-
pared to that of the control (25.9 months v 21.4
months, HR 1.71; P ¼ .01).55 Although study
D9902A was discontinued prematurely based on
the primary analysis of study D9901, it also demon-
strated a similar improvement in OS in the
sipuleucel-T group compared to the OS of the
control group (19.0 months v 15.7 months; HR
0.79; P ¼ .33), but the OS benefit did not reach
statistical significance.55 As a result, a third phase III
trial was conducted to confirm the OS benefit.
Approval of sipuleucel-T was supported mainly by
data from the pivotal phase III IMPACT trial
(D9902B).59 A total of 512 men with asympto-
matic/minimally symptomatic mCRPC were random-
ized 2:1 to receive sipuleucel-T or control infusions
of nonantigen-treated APCs. The primary endpoint
was met with a 22% reduction in risk of death (HR
0.78; P ¼ .03) in patients treated with sipuleucel-T
and a 4.1-month prolongation in median OS in
patients treated with sipuleucel-T compared to the
median OS in the control group (25.8 months v 21.7
months). The 3-year survival rate in the sipuleucel-T
group was 31.7% and 23.0% in the control group.
The side effects of sipuleucel-T are generally
infusion-related and self-limiting. Based on an inte-
grated safety analysis of 601 sipuleucel-T–treated
patients and 303 control patients treated in four
randomized phase III trials, the most frequently
reported AEs associated with sipuleucel-T were
chills, pyrexia, headache, myalgia, influenza-like ill-
ness, and hyperhidrosis.60 In general, these events
were mild or moderate in severity, occurred within
1 day of infusion, and resolved within 2 days. Given
the favorable toxicity profile and convenient route of
J.S. WeberS24administration, the success of sipuleucel-T has paved
the way for new vaccine treatment paradigms in
prostate cancer and other oncology indications.CURRENT THERAPEUTIC VACCINES IN PHASE
III DEVELOPMENT
The success of sipuleucel-T has encouraged the
development of other therapeutic prostate cancer
vaccines, including the tumor-cell based GVAX-PCa
and the viral vaccine Prostvac (Bavarian Nordic,
Mountain View, CA). GVAX-PCa contains a mixture
of two irradiated allogeneic prostate cancer cell lines
(LNCaP and PC-3) that have been genetically
modified to constitutively express GM-CSF.61,62
Although GVAX-PCa appeared to have promising
activity in early phase trials, two phase III trials,
known as VITAL-1 (NCT00089856) and VITAL-2
(NCT00133224), were prematurely terminated due
to a lack of therapeutic effect and increased mortal-
ity, respectively. Studies combining GVAX-PCa with
immune checkpoint inhibitors are ongoing. Rilimo-
gene-galvacirepvec/Prostvac, also known as PSA-TRI-
COM, is a recombinant viral vaccine. The primary
vaccination includes a recombinant vaccinia vector,
which is followed by multiple booster vaccinations
with a recombinant fowlpox vector. Both vectors
contain transgenes for PSA and three co-stimulatory
molecules (LFA-3 [CD58], ICAM-1 [CD54], and B7-1
[CD80]).63 The clinical potential of rilimogene-
galvacirepvec in patients with mCRPC has been
demonstrated in two phase II studies.64,65 Although
the first study (N ¼ 125) did not meet its primary
endpoint of improved PFS, there was a statistically
significant increase in OS among patients treated
with rilimogene-galvacirepvec compared to patients
treated with placebo (25.1 months v 16.6 months;
HR 0.56; P ¼ .006).64 The survival outcome was
subsequently confirmed in a smaller study (N ¼ 32)
in which median OS among rilimogene-galvacirep-
vec–treated patients was 26.6 months.65 Rilimogene-
galvacirepvec is currently being evaluated in the
phase III PROSPECT study (NCT01322490; Table 3).
Algenpantucel-L is currently the most clinically
advanced vaccine for pancreatic cancer. This cell-
based vaccine contains two irradiated human alloge-
neic pancreatic cancer cell lines that are engineered
to express the murine enzyme α-1,3-galactosyl trans-
ferase (αGT). This enzyme directs the synthesis of
α-galactosyl (αGal) epitopes on surface proteins and
glycolipids, which can boost immune responses to
tumor cells by making them appear as “foreign” to
the immune system.66 Binding of naturally occurring
anti-αGal antibodies to αGal epitopes on the tumor
cell lines activates complement-mediated lysis and
antibody-dependent cell-mediated toxicity. In aphase II study of algenpantucel-L plus standard of care
(SOC) treatment in patients (N ¼ 70) with resected
pancreatic cancer, the 1-year disease-free survival (DFS)
and OS rates were 62% and 86%, respectively, and 3-
year DFS and OS rates were 26% and 39%, respec-
tively.67–68 The most common AEs were induration
and pruritus at the sites of injection, which typically
resolved spontaneously within a week of onset.
Algenpantucel-L is currently being evaluated in two
phase III trials, IMPRESS (NCT01072981; Table 3) and
PILLAR (NCT01836432; Table 3).
The lipopeptide vaccine tecemotide is designed to
induce an immune response against cancer cells
expressing the cell-surface glycoprotein MUC1,
which is expressed on numerous cancers, including
NSCLC, and is involved in tumor growth and sur-
vival.69,70 Tecemotide is composed of the BLP25
lipopeptide, the immunoadjuvant monophosphoryl
lipid A, and several other lipids. It is being evaluated
in multiple tumor types, and to date the most
advanced results are from the phase III START trial
in patients (N ¼ 1513) with unresectable stage III
NSCLC.71 In a phase IIb trial of previously treated
patients with stage IIIb/IV NSCLC, tecemotide dem-
onstrated a nonsignificant improvement in OS com-
pared to the OS of best supportive care in patients
with locoregional disease,70–72 and this led to a phase
III trial in stage III NSCLC. Although the START trial
did not meet the primary endpoint of improved OS in
the overall patient population, a prespecified explor-
atory analysis demonstrated a statistically significant
improvement in patients who received tecemotide
after concurrent chemoradiotherapy compared to
that of patients who received placebo (30.8 months
v 20.6 months; HR 0.78; P ¼ .016). Of note, the FDA
placed a clinical hold on tecemotide after a patient
with multiple myeloma developed encephalitis in a
phase II study. The clinical hold has since been
lifted, and phase III development in NSCLC is con-
tinuing (START2 [NCT02049151] and INSPIRE
[NCT01015443]; Table 3); however, a phase III study
(STRIDE; NCT00925548) in women with advanced
breast cancer was terminated.73 Another peptide
vaccine being investigated in NSCLC and melanoma
targets the gene MAGEA3. Unlike MUC1, MAGEA3
is expressed almost exclusively on tumor cells. The
MAGE-A3 vaccine, administered intramuscularly
with the AS02B immunostimulant, was being inves-
tigated as adjuvant therapy in the MAGRIT trial
(NCT00480025) in patients with completely resected
NSCLC that expressed the MAGEA3 gene. This was
the largest adjuvant lung cancer trial ever conducted.
Unfortunately, this trial was recently closed because
an interim analysis showed that the vaccine failed to
significantly improve DFS. This vaccine also recently
failed in a phase III adjuvant trial in melanoma. These
failures highlight the challenges facing vaccines that
Table 3. Selected Ongoing Phase III Clinical Trials of Vaccines in Solid Tumors
NCT Number/Trial Name Treatment Arms Target Population N*
Primary
Endpoint Status
NCT01322490/ PROSPECT Rilimogene-galvacirepvec þ GM-
CSF
Asymptomatic/minimally symptomatic
mCRPC
1200 OS Currently
recruiting
Rilimogene-
galvacirepvec þ placebo
Placebo þ placebo
NCT01072981/ IMPRESS Algenpantucel-L þ GEM  5-FU
chemoradiation
Surgically resected pancreatic cancer 722 OS Ongoing
GEM  5-FU chemoradiation
NCT01836432/ PILLAR Algenpantucel-L þ FOLFIRINOX Borderline resectable or locally
advanced unresectable
pancreatic cancer
280 OS Currently
recruitingFOLFIRINOX
Algenpantucel-L þ GEM/Nab-PAC
GEM/Nab-PAC
NCT02049151/ START2 Tecemotide Completed concurrent chemo-
radiotherapy for
unresectable stage III NSCLC
1002 OS Currently
recruitingPlacebo
NCT01015443/ INSPIRE Tecemotide þ BSC Asian patients with unresectable
stage III NSCLC
500 OS Currently
recruitingPlacebo þ BSC
NCT01480479/ ACT IV Rindopepimut þ TMZ Newly diagnosed, surgically resected,
EGFRvIII-positive GBM
700 OS Currently
recruitingKLH (control) þ TMZ
n Planned enrollment.
Abbreviations: 5-FU, ﬂuorouracil; BSC, best supportive care; EGFR, epidermal growth factor receptor; FOLFIRINOX, 5-ﬂourouracil, leucovorin, oxaliplatin, and irinotecan; GBM, glioblastoma
multiforme; GEM, gemcitabine; GM-CSF, granulocyte-macrophage colony-stimulating factor; KLH, keyhole limpet hemocyanin; mCRPC, metastatic castration-resistant prostate cancer; Nab-
Pac, nab-paclitaxel; NCT, national clinical trial; NSCLC, non-small cell lung cancer; OS, overall survival; TMZ, temozolomide.
Source: clinicaltrials.gov
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induced immune suppression.
Rindopepimut, which is being evaluated in glio-
blastoma multiforme (GBM), is an epidermal growth
factor receptor variant III (EGFRvIII)-targeted pep-
tide vaccine.74 EGFRvIII is expressed in approxi-
mately one-third of primary GBM, but not in normal
tissue, and it is associated with poor long-term
survival.75,76 In three phase II trials (ACTIVATE
[N ¼ 18], ACT II [N ¼ 22], and ACT III [N ¼ 65]),
significantly higher PFS and OS were demonstrated
in patients with newly diagnosed GBM who were
treated with rindopepimut in combination with SOC
(temozolomide) compared with patients treated
with historic controls, as well as in comparison with
previous phase III trials. ACTIVATE, ACT II, and ACT
III demonstrated a PFS of 14.2 months, 15.2 months,
and 12.3 months, respectively, in the rindopepimut/
SOC groups and 6.3 months in the historic control
group, and an OS of 26.0 months, 23.6 months, and
24.6 months in the rindopepimut/SOC groups and
15.0 months in the historic control group.71,77–79
Toxicity was mainly limited to injection site reac-
tions, and was typically grade 2 or less. Rindopepi-
mut is currently being evaluated in the phase III ACT
IV study (NCT01480479; Table 3).CONCLUSIONS
The regulatory approvals of ipilimumab and sipu-
leucel-T, and the encouraging data from early clinical
trials of other immune checkpoint inhibitors and
novel vaccine strategies, have brought immunother-
apy to the forefront of cancer therapeutics and made
the goal of long-term tumor control seem achievable
by immunologic manipulation. Results from phase III
studies of mAbs targeting PD-1/PD-L1 and numerous
cancer vaccines in development are eagerly awaited.
The potential addition of these strategies to the
anticancer armamentarium is anticipated to provide
important benefits to patients. Emerging strategies
for cancer immunotherapy are reviewed within the
article by Brian Rini within this supplement.Acknowledgments
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